Compare STKE & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STKE | LUNG |
|---|---|---|
| Founded | 2002 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Industrial Specialties |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.4M | 72.2M |
| IPO Year | N/A | 2020 |
| Metric | STKE | LUNG |
|---|---|---|
| Price | $1.31 | $1.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 277.9K | ★ 339.5K |
| Earning Date | 02-25-2026 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,456,249.00 | ★ $91,664,000.00 |
| Revenue This Year | $45.67 | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.18 | 15.59 |
| 52 Week Low | $1.18 | $1.31 |
| 52 Week High | $24.88 | $9.37 |
| Indicator | STKE | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.